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Abstract
An analytical strategy based on matrix-assisted laser desorption/ionization 
(MALDI) time-of-flight (TOF) mass spectrometry (MS) for identification of peptides 
and proteins in illegally distributed products is presented. The identified compounds 
include human growth hormone (hGH), human somatoliberin, anti-obesity drug 
(AOD), growth hormone releasing peptides (GHRP-2 and GHRP-6), Glycine-GHRP-2 
and Glycine-GHRP-6, ipamorelin, insulin aspart and porcine, delta sleep-inducing 
peptide (DSIP), thymosin β4, insulin like growth factor (IGF), mechano growth 
factor (MGF), human chorionic gonadotropin (hCG), melanotan II, bremelanotide, 
dermorphin and body protecting compound (BPC 157). The identification of proteins 
was mainly based on peptide mass fingerprinting, i.e., bottom up approach, while the 
smaller peptides were identified through de-novo sequencing. In cases when a reference 
standard was available, complementary identification was performed by capillary 
electrophoresis in double-injection mode (DICE), where a suspicious product was 
compared with the reference standard through two consecutive injections within the 
same electrophoretic run.
Keywords: matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry, double-injection capillary electrophoresis, illegally distributed proteins 
and peptides
1. Introduction
A broad range of proteins and peptides, for various purposes of enhancement, 
such as human growth hormone (hGH), i.e., somatropin, can be obtained from the 
illicit market. These products are mainly marketed as lyophilized formulations in 
small glass containers often without labelling. The customers are exposed to a range 
of potential harms, besides from the active components, including bacterial and 
fungal or viral infections which may arise from the fact that they are administered 
parenterally.
Figure 1A illustrates the total number of injection vials containing white 
lyophilized product cake being seized by the Swedish Customs during nine years in 
the past, i.e., 2010–2018. A large proportion of these samples, i.e., 64%, contained 
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human growth hormone or melanotan II. About a third of the seized vials, i.e., 27%, 
did not contain any active peptide or protein, while the remaining 9% of the vials 
contained other compounds (Figure 1B).
The concept of a proteolytic peptide pattern, i.e., protein peptide mapping 
(PPM), being characteristic of a protein was first demonstrated by SDS-PAGE [1]. 
In 1989, peptide sequencing by automated Edman degradation had a cycle-time of 
nearly one hour per amino acid residue. Samples of interest often contained com-
plex mixtures of proteins, which usually required separation by SDS-PAGE followed 
by electroblotting onto a polyvinylidene fluoride (PVDF) membrane [2]. However, 
a more rapid approach to peptide sequencing is “peptide mass fingerprinting” 
(PMF). By PMF, proteins are enzymatically cleaved in a predictable manner and 
the sizes of the generated peptide fragments are specific for different proteins. 
Figure 1. 
Schematic illustration of the number of seized illicit products during 2010–2018 in Sweden (A), as well as the 
active peptides/proteins that have been identified in theses samples (B).
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Subsequent analysis of the obtained peptides by mass spectrometry (MS) generates 
mass-to-charge ratio (m/z) values in the mass spectrum which in turn give rise to 
a characteristic “peptide mass fingerprint” of the protein [3, 4]. The fingerprint 
serves to identify the protein by comparison with in silico digests, i.e., search 
engines attempt to match peptides from in silico digested proteins to those measured 
by the mass spectrometer [5–9]. Peptide mass fingerprinting with MS, which was 
first demonstrated with fast atom bombardment ionization in 1981, provides the 
possibility of identifying a protein at nanogram-level [5, 10–12]. Trypsin is a com-
monly used proteolytic enzyme for PMF, since it is relatively cheap, highly selec-
tive, and generates peptides with an average size of about 8–10 amino acids which 
are ideally suited for analysis by MS. It cleaves principally on the C-terminal side 
of arginine and lysine with the exception of Arg-Pro and Lys-Pro [2]. Limitations 
to protein identification by PMF include; I) The protein sequence must be present 
in a database for a successful protein identification. II) Proteins with extensive 
post-translational modifications may fail to yield good matches [13]. III) Different 
isoforms of a protein or alternatively spliced proteins may not be distinguished if 
the unique sequence regions are not observed in the peptide map. IV) Incomplete 
proteolytic digestion and differences in peptide ionization provide an incomplete 
mass fingerprint of the protein. Therefore, a complementary approach to PMF for 
protein identification is the use of tandem mass spectrometry (MS/MS), whereby 
tryptic peptide ions from the first stage of MS are dissociated along the backbone 
and then separated and detected in a second stage of MS to identify primary amino 
acid sequences [14–16]. Tandem mass spectrometry in conjunction with PMF 
provides even more specificity, thereby facilitating the identification [17, 18].
Since the innovation of sensitive commercial instrumentation based on MALDI-
TOF MS in 1992, the technique has been widely used for protein identification due 
to its high sensitivity and mass accuracy, speed, extremely low material consump-
tion, absence of multiple charge mass signals and relatively high tolerance toward 
additives and contaminants such as salts, matrix components and excipients 
[19–26]. Furthermore, MALDI is a micro-destructive analytical technique and the 
remaining material on the MALDI target plate can be archived for later analysis. 
The high sensitivity of MALDI implies that only a small aliquot of the digested 
protein is required for mass analysis, and the remainder can be used for alternative 
measurements. MALDI provides additional information regarding the primary 
structure of the protein by sequencing of selected tryptic peptide ions in post 
source decay (PSD) mode [27–34]. MALDI in-source decay (ISD) is another attrac-
tive method which generates partial sequence information of intact proteins with 
up to 20–50 amino acid residues [35] (Figure 2).
The sequence information from MALDI-PSD or MALDI-ISD analyses can 
be used to validate protein identification. The singly charged ions generated by 
MALDI-TOF-MS are a mixture of b-, y- and a-ions accompanied by ions resulting 
from neutral loss of ammonia or water [36–39].
PMF-based protein identification is accomplished by searching a protein 
sequence database using different search engines such as ProFound [40], Mascot 
[41], or SEQUEST [15]. A value-based scoring system has been developed that 
facilitates the identification without accompanying amino acid data [42, 43]. 
Parameters which are considered to be important for the identification include; 
molecular mass, protein sequence coverage and the number of matching peptides 
[42]. However, presence of a signature peptide, being unique for a protein, facili-
tates the PMF-based identifications [44]. Prior reports suggest that a minimum of 
four matching peptides and a sequence coverage of at least 20% is necessary for 
positive PMF-based protein identification [45, 46]. The other alternative strategy 
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for protein identification is the top down approach, where intact molecule ions are 
subjected to gas-phase fragmentation [47].
Proteins with posttranslational modifications, such as glycosylation, pres-
ent additional challenges since the masses of the modified peptides are different 
and thus do not contribute to the identification. In such cases, the protein can be 
analyzed by capillary electrophoresis (CE), in order to explore the heterogeneity 
of the protein followed by comparison of its electropherogram with that of the 
corresponding reference standard [13, 48].
2. Experimental
2.1 Sample preparation
MALDI-TOF-MS is very tolerant to salts and sample matrices, hence it is seldom 
necessary to desalt the sample. However, sometimes it is necessary to use a C18 
micro-column in order to fractionate a complex sample or enhance the target analyte 
concentration.
The sample to be analyzed is mixed with a matrix solution (1:1, v:v), e.g. 
sinapinic acid (SA) or alpha-cyano-4-hydroxycinnamic acid (ACHCA). One μl of 
the mixture is deposited on the MALDI target plate and allowed to air-dry (i.e., the 
dried-droplet method) before being placed in the mass spectrometer [19, 49].
2.2 Proteolysis
The analyte to be digested is dissolved in ammonium bicarbonate (50 mM, 
pH 7.9). The intact sample is directly analyzed by MALDI in order to determine the 
molecular mass of the analyte. Then, 200 μl of the solution is digested by addition 
of 2–10 μl trypsin (200 μg/ml in 10 mM HCl). The reaction is carried out at room 
temperature or at 37°C for 30 minutes up to 24 hours, depending on peptide or pro-
tein in question. It has been found that 30 minutes digestion of somatropin at room 
temperature generated enough tryptic fragments for the MALDI analyses [50]. For 
more complex proteins, such as human chorionic gonadotropin, the required time 
Figure 2. 
MALDI in source decay analysis of a suspected illegal somatropin sample. The blue marked amino acid asp 
(D) is the deamidated form of Asn (N).
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period for proteolysis is found to be 24 hours at 37°C. Insulin porcine is digested at 
37°C for 12 hours, while other peptides are digested at 37°C for 4 hours. In order 
to enable alkylation of the cysteine residues in a protein or peptide, it is reduced 
by using DTT or 2-mercaptoethanol (ME) followed by labelling of the free thiol 
groups with 2-iodoacetamide. The alkylation is carried out through the following 
procedure:
1. 2.5 μl 100 mM ME is added to 10 μl of the protein solution.
2. The protein is then incubated at 50°C for 15 minutes to reduce the S-S linkages.
3. 2.5 μl 2-iodoacetamide (100 mM) is added into the mixture to interact with 
free sulfide groups of the cysteine residues at +4°C for 15 to 60 minutes in 
darkness.
4. 2.5 μl (10 μg/mL) trypsin is added to the mixture for the digestion. The reaction 
is performed at room temperature or at 37°C [13, 50].
2.3 Apparatus and operating conditions
MALDI-TOF analyses are performed using either an Autoflex or an Autoflex Max 
(Bruker Daltonics, Bremen, Germany) reflector type time-of-flight mass spectrom-
eter, equipped with a pulsed nitrogen laser working at 337 nm and a smartbeam II 
laser working at 355 nm, respectively. The Autoflex instrument is operated in the 
positive ion mode with delayed extraction at an accelerating voltage of 20 kV and a 
variable voltage reflectron. The parameter settings are optimized to analyze peptides 
in reflectron mode. Before analysis, the instrument is externally calibrated with 
Bruker Daltonics standard peptide or protein mixtures. Peptide mass peaks occur-
ring due to autolysis of trypsin (porcine) such as 842.51 and 2211.10 Da are also used 
for internal calibration. Mass spectra are obtained by averaging 250 laser shots (5× 50 
shots) at different positions on the sample surface. All samples being used for post 
source decay (PSD) analysis are analyzed in the reflectron mode. The autoflex Max 
instrument TOF/TOF (2 kHz MS and 200 Hz MS/MS) operates in the positive ion 
mode. Metastable fragmentation is induced by laser (355 nm) without the further 
use of collision gas. The lyophilized samples are dissolved in 300 μL ammonium 
bicarbonate buffer (50 mM, pH 7.5). The liquid samples are diluted with same buffer. 
The wells of MALDI plate are spotted with 1 μl sample/matrix solution (1:1, v:v) and 
allowed to air dry before being placed in the mass spectrometer. ACHCA is used for 
analysis of peptides. About 20 mg of ACHCA is mixed in 1 ml of ethanol: acetonitrile 
(ACN) (1: 1 v/v) and 0.1% trifluoroacetic acid (TFA). SA is used for protein analysis. 
Two different solutions of SA in water and ethanol are made as follows: 1 - Saturated 
solution of SA in ethanol and 0.1% TFA; 2 - Saturated solution of SA in 50% acetoni-
trile (ACN) and 0.1% TFA. Solution 1 is first applied on the MALDI plate on which 
the sample mixed with SA in 50% ACN and 0.1% TFA (1: 1) is then applied.
3. Results and discussion
Illegally distributed lyophilized or liquid products being suspected to contain 
pharmacologically active peptides were seized by the Swedish customs. The analyte 
to be identified is analyzed in both reflectron and linear modes in order to deter-
mine its molecular mass (Figure 3). Large peptides and proteins are then exposed 
to trypsin digestion in order to obtain peptide-mass map upon MALDI analysis in 
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reflectron mode. Small peptides are, on the other hand, analyzed in reflectron mode 
and/or PSD mode directly. This strategy was applied to the identification of the 
following peptides and proteins (Figure 4 and Table 1).
3.1 Identification of somatropin (hGH)
Recombinant hGH or somatropin consists of 191 amino acids with two disulfide 
bridges (Cys53-Cys165 and Cys182-Cys189) and promotes proteinogenesis as well as 
Figure 3. 
The sample to be identified is analyzed in both reflectron and linear modes in order to determine the molecular 
mass of the analyte. Depending on the size of the molecule it will be exposed to enzymatic digestion in order to 
be identified through PMF. Small peptides used to be identified by de novo sequencing in PSD mode.
Figure 4. 
The primary structure of the analyzed peptides. (A) Somatoliberin, (B) AOD, (C) GHRP-2, (D) glycine-
GHRP-2, (E) GHRP-6, (F) glycine-GHRP-2, (G) Ipamorelin, (H) MGF, (I) long-R3-IGF (disulfide bridges: 
C6-C48; C47-C52 and C18-C61; asp at position 3 is replaced by Arg), (J) insulin Aspart, (K) insulin porcine,  
(L) DSIP, (M) Thymosine β4, (N) Melanotan II, (O) Bremelanotide, (P) Dermorphin and (Q ) BPC 157. For 
molecular structures of somatropin and hCG see references [13, 50].
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fat mobilization and oxidation [51–53]. Recombinant hGH is used as a prescription 
drug to treat children’s growth disorders and adult growth hormone deficiency. In 
the belief that the beneficial impact of somatropin on the growth can be extrapo-
lated to healthy individuals, it is abused by bodybuilders and athletes [54]. However, 
many users are unaware of the correct dosage and how to prepare the solution for 
giving an injection. It has been demonstrated that supra-physiological dosages can 
have fatal consequences [55]. Apart from the undesired consequences following 
the abuse of somatropin, our investigations have shown that the illegally marketed 
products contained high levels of impurities such as endotoxins [50]. Endotoxins are 
associated with Gram-negative bacteria which can cause severe immune response 
and diseases in humans [56, 57]. Somatropin was identified through PMF and 
MALDI-ISD (see Figure 2)[48, 58, 59]. The availability of a compendial reference 
Peptide Mmass PMF
a PSDb ISDc DICZEd NMR LC/MS
Somatropin 22115.07
22128.68e
X — X X X X
Human 
Somatoliberin
3366.866 X X — — — —
AOD (Anti Obesity 
Drug) HGH 
fragment 177–191
1813.850 X X — — — —
GHRP-2 817.397 — X — — — —
Gly-GHRP-2 874.419 — X — — — —
GHRP-6 872.433 — X — — — —
Gly-GHRP-6 929.455 — X — — — —
Ipamorelin 711.385 — X — — — —
MGF 2866.469 X X — — — —
Long-R3-IGF 9105.385
9111.576e
X X — — — —
Insulin Porcine 5772.766 X X — X X X
Insulin Aspart 5821.611 X X — X X X
DSIP 848.318 — X — — — —
Thymosin-β4 4960.474 X X — — — —






X X — X — —
Melanotan-II 1023.502 — X — — X —
Bremelanotide 1024.510 — X — — X —
Dermorphin 802.337 — X — — X X
BPC-157 1418.692 — X — — X X
Albumin bovinef > 66,000e X — — — — —
aIdentification by peptide mass fingerprinting using enzymatic degradation as well as other modifications.
bDe novo sequencing by MALDI- post source decay.
cProtein sequencing by MALDI- in source decay.
dIdentification and/or impurity profiling by double injection capillary zone electrophoresis.
eAverage molecular mass.
fBovin albumin was detected in some of the samples.
Table 1. 
Illegally distributed peptides and proteins that have been analyzed by MALDI-ToF-MS and DICZE. The 
monoisotopic mass (Mmass) of the analytes and the employed analytical methodology is indicated.
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standard has made it possible to apply double injection capillary zone electropho-
resis (DICZE) for both identification and impurity determination of somatropin 
products [50, 58, 59]. The DICZE-method provided complementary information on 
the native protein, providing a side by side comparison between the electrophoretic 
patterns of the reference standard and the analyte to be identified [50].
3.2 Identification of human somatoliberin
Human somatoliberin, growth hormone-releasing hormone (GHRH), consti-
tutes of 44 amino acids without any post-translational modification or disulfide 
bridge. Somatoliberin was first isolated from two pancreatic islet cell tumors, and 
subsequently from normal human hypothalamus [60–62]. The MALDI results from 
determination of the molecular mass, PMF and amino acid sequence revealed that 
the Asn8 (N), Gly15 (G) and Met27 (M) residues have, respectively, been replaced by 
Gln8 (Q ), Ala15 (A) and Leu27 (L) during the synthesis (see Figures 4 and 5). The 
peptide was successfully identified by PMF and de-novo sequencing of three of the 
tryptic peptides.
3.3 Identification of an anti-obesity drug (AOD)
The AOD peptide is a fragment of the C-terminus of human growth hormone 
(fragment 177–191) where a tyrosine is added at the N-terminus. It is a cyclic 
peptide consisting of 16 amino acids with a disulfide bridge between cysteine 
residues at positions 7 and 14 in the peptide chain [63] (Figure 4 and Table 1). The 
fragment is the minimum length of the hGH sequence that retains the lipolytic 
and antilipogenic properties of hGH [63–65]. The molecular peptide masses of its 
tryptic peptides complied with the peptide map of hGH fragment 177–191. The 
existence of the disulfide bridge between C7 and C14 was confirmed upon analysis of 
the non-reduced tryptic sample (Figure 6). This peptide has also been employed as 
a signature peptide for the identification of hGH [48, 50]. The amino acid sequences 
of three selected tryptic peptides were also confirmed.
3.4 Identification of growth hormone releasing peptides (GHRP)
GHRP, including GHRP-2, GHRP-6, Gly-GHRP-2, Gly-GHRP-6 and ipamorelin, 
as an agonist of the gut peptide ghrelin is an endogenous ligand for the growth 
Figure 5. 
MALDI-PMF (A) and MALDI-PSD (B) analysis of somatoliberin.
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hormone secretagogue receptor [66, 67]. Ghrelin strongly stimulates food intake 
and GH release in humans [68–70]. These peptides were identified through de-
novo sequencing. The amino acid sequence of GHRP-6 differs slightly from that of 
GHRP-2, i.e., the amino acid residues dA and Naphthyl alanine (NalA) in GHRP2 
are replaced by H and dW in GHRP-6 (Figure 4 and Table 1) [70].
Ipamorelin is a penta-peptide, being derived from GHRP-1 [71]. Ipamorelin 
like the other GHR-peptides, stimulates production of growth hormone [72]. 
Incorporation of aminoisobutyric acid (Aib) in the peptide chain increases the 
stability of the peptide (Figure 4) [73].
3.5  Identification of mechano growth factor (MGF) and long-R3 insulin-like 
growth factor (IGF-1)
MGF is a unique, spliced variant of IGF-1. MGF induces muscle cell prolifera-
tion in response to muscle stress and injury [74]. MGF and Long-R3-IGF1 were 
identified in several confiscated samples. Long-R3-IGF-1, an analogue of IGF-1, 
has 13 additional amino acids at its N-terminus (Figure 4 and Table 1). IGF-1 
mediates the anabolic and mitogenic activity of GH [75–77]. MGF and Long-
R3-IGF1 were identified by sequence coverages of 100% and 43%, respectively 
(Table 2 and Figure 7).
3.6 Identification of insulin porcine and insulin aspart
Insulin regulates the cellular uptake, utilization, and storage of glucose, 
amino acids, and fatty acids and inhibits the breakdown of glycogen, protein, 
and fat. Since more than one decade ago the illegal use of insulin has been noticed 
Figure 6. 
MALDI-PSD analysis of AOD.
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[78]. However, the misuse and wrong administration of insulin could cause the, 
so called, dead in the bed syndrome [79]. In bodybuilding, insulin works such 
as testosterone or hGH to consolidate muscle tissue. Insulin also prevents break-
down of muscles and vanishes rapidly from the body, since it has a very short 
half-time (t1/2) [80].
Figure 7. 
MALDI analysis of intact long-R3-IGF and MALDI-PSD analysis of two tryptic peptides, i.e., m/z 1667.771 
and m/z 1763.887.





Glu-C digestion of the peptidea:
YQPPSTNKNTKSQRRKGSTFEE 2584.809 2584.816






aGlu-C cleaves at the C-terminus of either aspartic or glutamic acid residues.
bThe amino acid sequence of the peptide was determined.
Table 2. 
MALDI peptide mass fingerprinting-data from analysis of mechano growth factor.
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Several illegal products containing insulin porcine or aspart have been analyzed. 
Insulin is composed of two peptide chains, i.e., A and B, which are joined by two 
inter-chain disulfide bonds. The A chain also contains an intra-chain disulfide bond 
(Figure 4). The results summarized in Table 3, demonstrate the applied strategy 
for the identification of porcine and insulin aspart. The insulin molecules were 
reduced using a potent reducing agent, i.e., 2-mercaptoethanol (ME). MS-analysis 
of the reduced samples resulted in a mass spectrum consisting of several signals 
from both reduced A and B chains. The A and B chains generated three and four 
signals, respectively, corresponding to the ME-modified peptide as described in 
Table 3. It is to be noted that the amino acid residues P and A at positions 28 and 
30 in the B-chain, respectively, have been replaced by D and T in insulin aspart. 
Therefore, these insulin molecules are distinguished upon these differences. The 
tryptic digestion of the B chain yielded three peptide fragments of different sizes 
(Figure 8 and Table 3). The molecular masses of these peptides were determined 






Porcine (intact) 5774.635 5774.632
Aspart (intact) 5822.612 5822.618
Peptide chains from Insulin porcine:
[A-chain + Na]+ 2404.990 2404.758
[A-chain +1ME + Na]+a 2480.988 2480.769
[B-chain + H]+ 3398.682 3398.460
[B-chain +1ME + H]+a 3474.680 3474.486
Peptide chain from Insulin aspart:b
[B-chain + H]+ 3446.667 3446.434
[B-chain + Na]+ 3468.648 3468.487
[B-chain +1ME + H]+a 3522.665 3522.422
[B-chain - (GFFYTDKT) + H]+c 2487.228 2487.030
[B-chain - (GFFYTDKT) + 1ME + H]+a, c 2563.226 2563.302
Tryptic peptides from Insulin aspart:
[GFFYTDK + H]+ 877.399 877.317
[GFFYTDKT + H]+ 978.457 978.446
[B-chain - (GFFYTDKT) + H]+c, d 2487.217 2487.030
Tryptic peptides from Insulin porcine:
[GFFYTPK + H]+ 859.425 859.345
[GFFYTPKA + H]+ 930.462 930.337
[B-chain - (GFFYTPKA) + H]+c 2487.228 2487.234
[B-chain-(GFFYTPKA) + 1ME + H]+ a, c 2563.226 2563.129
aBeta mercaptoethanol (ME) was used as reducing agent.
bThe A-chains of insulin aspart and Insulin porcine are identical.
cTrypsinated B-chain.
dThese peptides originate from insulin aspart, see Figure 8.
Table 3. 
MALDI-TOF-MS analysis of insulin porcine and aspart.
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Double-injection capillary electrophoresis has also been applied for the identifi-
cation of insulin molecules [81].
3.7 Identification of delta sleep-inducing peptide (DSIP)
The nonapeptide delta DSIP was first isolated from the cerebral venous blood 
of rabbits in an induced state of sleep during the mid-70s [82]. It was primarily 
believed to be involved in sleep regulation due to its apparent ability to induce slow-
wave sleep in rabbits. However, it has been demonstrated that short-term treatment 
of chronic insomnia with DSIP is not likely to be of major therapeutic benefit [83]. 
The peptide is marketed illegally presumably for the treatment of insomnia. The 
peptide was directly exposed to the PSD analysis in order to confirm its molecular 
mass and amino acid sequence (Figure 4 and Table 1).
Figure 8. 
MALDI analysis of insulin aspart; analysis of reduced B-chain (A), MALDI-PSD analysis of tryptic B-chain 
(B), see Table 3.
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3.8 Identification of thymosin β4
Synthetic thymosin is a peptide consisting of 43 amino acids with artificial 
acetylation of the N-terminus (see Figure 4 and Table 1). Thymosin has the 
potential of playing a significant role in tissue development, maintenance, repair, 
pathology and other important biological activities [84]. Some important biological 
activities of thymosin are related to the peptide sequence L17KKTET22 [85]. Illegally 
distributed thymosin products are claimed to promote a variety of beneficial 
biological functions, such as muscle building. The peptide was identified through 
PMF and de-novo sequencing of the tryptic peptides (Table 4).
3.9 Identification of human chorionic gonadotropin (hCG)
Human chorionic gonadotropin (hCG) is a glycoprotein hormone consisting of α 
(92 amino acids) and β-subunits (145 amino acids) being noncovalently associated 
[86]. These subunits are, however, highly cross-linked internally through disulfide 
bridges, i.e., the α-subunit has five disulfide bridges [87], while the β-subunit has 
six [87, 88]. The protein is heavily glycosylated where oligosaccharides are attached 
to the protein backbone through asparagine and serine residues and constitute 
approximately 30% of the molecular mass [89]. The protein has been identified 
using MALDI-TOF-MS and DICZE [13, 50]. Approximately 40% of the amino acid 
sequence of hCG was confirmed upon PMF (Table 5) [13].
























aThe amino acid sequence of the peptide was determined in the PSD mode.
bN.D. = Not detected.
Table 4. 
MALDI peptide mass fingerprinting data from analysis of thymosin β4.
Mass Spectrometry in Life Sciences and Clinical Laboratory
14
The identification was confirmed by DICZE analysis of illegal samples together 
with the corresponding reference standard [13, 50].
3.10 Identification of melanotan II (MII) and bremelanotide
Melanotan, a melanocortin receptor agonist, is a cyclic-lactam bridge heptapep-
tide which induces melanogenesis (i.e., tanning of the skin), by activation of the MC1 
receptor, being an analogue to alpha melanocyte hormone (α-MSH) [90]. The cyclic, 
lactam bridged structure of MII induces increased lipophilicity (Figure 4) [91].
Skin-tanning products that claim to contain MII are being advertised and sold on 
the illicit drug market. Injection of MII can result in systemic toxicity and rhabdomy-
olysis [90]. Bremelanotide (formerly PT-141) is an active metabolite of MII (Table 1).
These peptides were identified through the top-down approach by MALDI in 
PSD mode as illustrated in Figure 9.
3.11 Identification of dermorphin
Dermorphin is a μ-opioid receptor-binding peptide that causes both central 
and peripheral effects [92] (Figure 4 and Table 1). This peptide, being originally 
isolated from the skin of the south American tree frog Phyllomedusa sauvagii, is 
classified as one of the strongest mammalian endogenous analgesic opioids [93, 94]. 
Dried frog skin containing dermorphin, has been used as a therapeutic agent by the 
Matses tribes of the upper Amazonian basin, to treat cuts during hunting expedi-
tions [95]. The analgetic effects of dermorphin has been demonstrated in rat, horse, 
dog and white sea cod [92, 94]. It has been used illegally in horse racing as a pain 
killing agent, allowing horses to run even if injured.
This peptide, which was detected in several samples, was identified by MALDI 
in the PSD mode (Figure 10). The molecular structure was confirmed by NMR 
spectroscopy.
3.12 Identification of body protecting compound 157 (BPC 157)
BPC 157 being a partial sequence of body protecting compound (BPC) 
(Mmass = 40 kDa) is a synthetic peptide, which is composed of fifteen amino acids 
Peptide 
fragments
Peptide position in the 
peptide chain
Theoretical m/z  
[M + H]+
Determined m/z  
[M + H]+
AYPTPLR α-hCG; 36–42 817.446 817.482
TMLVQK α-hCG; 46–51 719.402 719.414
STNR α-hCG; 64–67 477.231 477.165
VTVMGGFK α-hCG; 68–75 838.439 838.471
SK β-hCG; 1–2 234.135 243.142
PR β-hCG; 7–8 272.161 271.996
EPLR β-hCG; 3–6 514.288 514.291
EPLRPR β-hCG; 3–8 767.442 767.469
DVR β-hCG; 61–63 389.204 389.228
FESIR β-hCG; 64–68 651.336 651.359
Table 5. 
MALDI-PMF and MALDI-PSD analysis of human chorionic gonadotropin. The identified peptides from the α 
and β subunits are presented in the table below.
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(Figure 4 and Table 1). BPC was discovered and isolated from mouse gastric 
juice in response to stress stimuli in the gut mucosa [96]. BPC 157 is also known as 
Bepcin and PL. 14,736 or PL 10 [97]. This peptide fragment was speculated to be 
responsible for the BPC’s physiological and protective effects [96]. However, it is 
unclear whether this peptide is endogenous to humans. BPC 157 is suggested to aid 
in tendon, ligament and muscle healing, and therefore its use as a quick injury heal-
ing in the sporting world is appealing. However, no proper clinical trials in human 
subjects have yet been performed to investigate the healing capability and the harm-
ful effects of this compound [97].
Figure 9. 
MALDI-PSD analysis of melanotan II.
Figure 10. 
MALDI-PSD analysis of dermorphin.
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BPC 157 was recently identified in several confiscated vials for injection. 
The identification was carried out by MALDI in both PSD and reflectron modes 
(Figure 11). The amino acid sequence of the peptide was confirmed by NMR 
 spectroscopy and LC-QTOF-MS.
4. Conclusions
The proposed methods, based on PMF by MALDI-TOF-MS as well as analysis 
with DICZE, provided an efficient procedure for the identification of peptides and 
proteins in illegally distributed samples. The use of trypsin as a proteolytic enzyme 
generated peptide fragments which covered 40 to 80% of the amino acid sequences 
of the analyzed proteins. The presence of a signature peptide in the peptide map 
facilitated the analyte identification considerably. MALDI-TOF-MS was also applied 
in the PSD mode for the amino acid sequencing of selected tryptic peptides as well 
as small peptides, such as ipamorelin.
The double-injection CE method provided complementary information on the 
native protein in the presence of a reference standard. This provided the possibility 
of performing a comparison between the electrophoretic patterns of the reference 
standard and the analyte to be identified. In addition, the double-injection based 
identifications were carried out by comparing the corrected migration time of the 





BPC Body protecting compound
Figure 11. 
MALDI-PSD analysis of BPC 157.
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